Compare MATW & SLS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | MATW | SLS |
|---|---|---|
| Founded | 1850 | 2012 |
| Country | United States | United States |
| Employees | 5500 | N/A |
| Industry | Metal Fabrications | Biotechnology: Pharmaceutical Preparations |
| Sector | Telecommunications | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 825.3M | 924.5M |
| IPO Year | 1995 | 2007 |
| Metric | MATW | SLS |
|---|---|---|
| Price | $26.73 | $7.72 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $10.00 |
| AVG Volume (30 Days) | 187.6K | ★ 7.6M |
| Earning Date | 04-30-2026 | 05-11-2026 |
| Dividend Yield | ★ 3.67% | N/A |
| EPS Growth | ★ 59.07 | 50.00 |
| EPS | ★ 0.69 | N/A |
| Revenue | ★ $1,795,737,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $110.98 |
| P/E Ratio | $38.43 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $20.73 | $1.39 |
| 52 Week High | $30.93 | $9.10 |
| Indicator | MATW | SLS |
|---|---|---|
| Relative Strength Index (RSI) | 44.47 | 64.01 |
| Support Level | $26.48 | $3.72 |
| Resistance Level | $27.41 | N/A |
| Average True Range (ATR) | 0.91 | 0.69 |
| MACD | -0.21 | 0.24 |
| Stochastic Oscillator | 13.19 | 67.02 |
Matthews International Corp is a provider of memorialization products, industrial technologies and brand solutions. The company's segments are Memorialization, Industrial Technologies and Brand Solutions. The memorialization offerings include bronze and granite memorials, caskets, and cremation-related products and equipment for cemeteries and funeral homes. Its Industrial Technologies segment designs, manufactures, services, and sells custom energy storage systems and product identification and warehouse automation solutions. The Brand Solutions segment provides brand management, pre-media, printing plates and cylinders, imaging, digital asset management, merchandising displays, and marketing and design services. The majority of revenue is generated by Memorialization.
SELLAS Life Sciences Group Inc is a late-stage clinical biopharmaceutical company focused on the development of novel therapeutics for a broad range of cancer indications. The company's product candidates currently include galinpepimut-S, or GPS, a peptide immunotherapy directed against the Wilms tumor 1, or WT1, antigen, and GFH009, a selective small molecule cyclin-dependent kinase 9, or CDK9, inhibitor.